Cutler Group LP Argenx Se Put Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Jan 18, 2024	BUY	$338.91 - $506.01 $67,782 - $101,202	200 Added 50.0%	600 $10,000
Q3 2023 Nov 07, 2023	BUY	$369.35 - $548.43 $147,740 - $219,371	400 New	400 $19,000
Q3 2020 Oct 27, 2020	SELL	$215.51 - $272.51 $969,795 - $1.23 Million	-4,500 Reduced 69.23%	2,000 $3,000
Q2 2020 Jul 22, 2020	BUY	$127.44 - $232.72 $560,736 - $1.02 Million	4,400 Added 209.52%	6,500 $31,000
Q1 2020 May 07, 2020	SELL	$108.83 - $165.23 $370,022 - $561,782	-3,400 Reduced 61.82%	2,100 $65,000
Q4 2019 Feb 06, 2020	BUY	$106.59 - $164.21 $266,475 - $410,525	2,500 Added 83.33%	5,500 $5,000
Q3 2019 Oct 28, 2019	SELL	$113.31 - $150.51 $362,592 - $481,632	-3,200 Reduced 51.61%	3,000 $17,000
Q2 2019 Aug 09, 2019	BUY	$115.0 - $141.58 $563,500 - $693,742	4,900 Added 376.92%	6,200 $20,000
Q1 2019 May 10, 2019	BUY	$98.85 - $134.59 $9,885 - $13,459	100 Added 8.33%	1,300 $4,000
Q4 2018 Feb 05, 2019	BUY	$63.81 - $109.82 $12,762 - $21,964	200 Added 20.0%	1,200 $16,000
Q3 2018 Nov 07, 2018	BUY	$75.5 - $96.63 $75,500 - $96,630	1,000 New	1,000 $10,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.